Real-World data shows Tezepelumab's impact on severe asthma patients

NCT ID NCT07013760

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 34 times

Summary

This study reviewed medical records of 420 people with severe asthma who received tezepelumab after it was approved in Spain. The goal was to see how patients fared in real life, including asthma attacks and symptom control. It did not test a new treatment but gathered information on existing use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Andalucia, Spain
Research Site

C. Valenciana, Spain
Research Site

C. Y Leon, Spain
Research Site

Cantabria, Spain
Research Site

Castilla La Mancha, Spain
Research Site

Cataluna, Spain
Research Site

Extremadura, Spain
Research Site

Galicia, Spain
Research Site

Islas Canarias, Spain
Research Site

Madrid, Spain
Research Site

Navarra, Spain
Research Site

Pais Vasco, Spain

Conditions

Explore the condition pages connected to this study.

ASTHMA